94 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Langbehn DR, Hersch S. Clinical Outcomes and Selection Criteria for Prodromal Huntington's Disease Trials. Movement Disorders. PMID 32686867 DOI: 10.1002/Mds.28222  0.341
2018 Stephen CD, Hung J, Schifitto G, Hersch SM, Rosas HD. Electrocardiogram Abnormalities Suggest Aberrant Cardiac Conduction in Huntington's Disease. Movement Disorders Clinical Practice. 5: 306-311. PMID 30363459 DOI: 10.1002/Mdc3.12596  0.303
2018 Rosas HD, Wilkens P, Salat DH, Mercaldo ND, Vangel M, Yendiki AY, Hersch SM. Complex spatial and temporally defined myelin and axonal degeneration in Huntington disease. Neuroimage. Clinical. 20: 236-242. PMID 30090698 DOI: 10.1016/J.Nicl.2018.01.029  0.303
2017 Schobel SA, Palermo G, Auinger P, Long JD, Ma S, Khwaja OS, Trundell D, Cudkowicz M, Hersch S, Sampaio C, Dorsey ER, Leavitt BR, Kieburtz KD, Sevigny JJ, Langbehn DR, et al. Motor, cognitive, and functional declines contribute to a single progressive factor in early HD. Neurology. PMID 29142089 DOI: 10.1212/Wnl.0000000000004743  0.321
2017 Hersch SM, Schifitto G, Oakes D, Bredlau AL, Meyers CM, Nahin R, Rosas HD. The CREST-E study of creatine for Huntington disease: A randomized controlled trial. Neurology. PMID 28701493 DOI: 10.1212/Wnl.0000000000004209  0.323
2017 Quinti L, Dayalan Naidu S, Träger U, Chen X, Kegel-Gleason K, Llères D, Connolly C, Chopra V, Low C, Moniot S, Sapp E, Tousley AR, Vodicka P, Van Kanegan MJ, Kaltenbach LS, ... ... Hersch SM, et al. KEAP1-modifying small molecule reveals muted NRF2 signaling responses in neural stem cells from Huntington's disease patients. Proceedings of the National Academy of Sciences of the United States of America. PMID 28533375 DOI: 10.1073/Pnas.1614943114  0.321
2016 Chopra V, Quinti L, Khanna P, Paganetti P, Kuhn R, Young AB, Kazantsev AG, Hersch S. LBH589, A Hydroxamic Acid-Derived HDAC Inhibitor, is Neuroprotective in Mouse Models of Huntington's Disease. Journal of Huntington's Disease. 5: 347-355. PMID 27983565 DOI: 10.3233/Jhd-160226  0.376
2015 Rosas HD, Doros G, Bhasin S, Thomas B, Gevorkian S, Malarick K, Matson W, Hersch SM. A systems-level "misunderstanding": the plasma metabolome in Huntington's disease. Annals of Clinical and Translational Neurology. 2: 756-68. PMID 26273688 DOI: 10.1002/Acn3.214  0.415
2014 Lu Z, Marks E, Chen J, Moline J, Barrows L, Raisbeck M, Volitakis I, Cherny RA, Chopra V, Bush AI, Hersch S, Fox JH. Altered selenium status in Huntington's disease: neuroprotection by selenite in the N171-82Q mouse model. Neurobiology of Disease. 71: 34-42. PMID 25014023 DOI: 10.1016/J.Nbd.2014.06.022  0.403
2014 Rosas HD, Doros G, Gevorkian S, Malarick K, Reuter M, Coutu JP, Triggs TD, Wilkens PJ, Matson W, Salat DH, Hersch SM. PRECREST: a phase II prevention and biomarker trial of creatine in at-risk Huntington disease. Neurology. 82: 850-7. PMID 24510496 DOI: 10.1212/Wnl.0000000000000187  0.324
2013 Chen J, Marks E, Lai B, Zhang Z, Duce JA, Lam LQ, Volitakis I, Bush AI, Hersch S, Fox JH. Iron accumulates in Huntington's disease neurons: protection by deferoxamine. Plos One. 8: e77023. PMID 24146952 DOI: 10.1371/Journal.Pone.0077023  0.335
2013 Moscovitch-Lopatin M, Goodman RE, Eberly S, Ritch JJ, Rosas HD, Matson S, Matson W, Oakes D, Young AB, Shoulson I, Hersch SM. HTRF analysis of soluble huntingtin in PHAROS PBMCs. Neurology. 81: 1134-40. PMID 23966247 DOI: 10.1212/Wnl.0B013E3182A55Ede  0.321
2013 Ramos EM, Latourelle JC, Gillis T, Mysore JS, Squitieri F, Di Pardo A, Di Donato S, Gellera C, Hayden MR, Morrison PJ, Nance M, Ross CA, Margolis RL, Gomez-Tortosa E, Ayuso C, ... ... Hersch SM, et al. Candidate glutamatergic and dopaminergic pathway gene variants do not influence Huntington's disease motor onset. Neurogenetics. 14: 173-9. PMID 23644918 DOI: 10.1007/S10048-013-0364-Y  0.334
2013 Thomas B, Matson S, Chopra V, Sun L, Sharma S, Hersch S, Rosas HD, Scherzer C, Ferrante R, Matson W. A novel method for detecting 7-methyl guanine reveals aberrant methylation levels in Huntington disease. Analytical Biochemistry. 436: 112-20. PMID 23416183 DOI: 10.1016/J.Ab.2013.01.035  0.315
2012 Chopra V, Quinti L, Kim J, Vollor L, Narayanan KL, Edgerly C, Cipicchio PM, Lauver MA, Choi SH, Silverman RB, Ferrante RJ, Hersch S, Kazantsev AG. The sirtuin 2 inhibitor AK-7 is neuroprotective in Huntington's disease mouse models. Cell Reports. 2: 1492-7. PMID 23200855 DOI: 10.1016/J.Celrep.2012.11.001  0.425
2012 Ramos EM, Latourelle JC, Lee JH, Gillis T, Mysore JS, Squitieri F, Di Pardo A, Di Donato S, Hayden MR, Morrison PJ, Nance M, Ross CA, Margolis RL, Gomez-Tortosa E, Ayuso C, ... ... Hersch SM, et al. Population stratification may bias analysis of PGC-1α as a modifier of age at Huntington disease motor onset. Human Genetics. 131: 1833-40. PMID 22825315 DOI: 10.1007/S00439-012-1205-Z  0.308
2012 Lee JH, Lee JM, Ramos EM, Gillis T, Mysore JS, Kishikawa S, Hadzi T, Hendricks AE, Hayden MR, Morrison PJ, Nance M, Ross CA, Margolis RL, Squitieri F, Gellera C, ... ... Hersch SM, et al. TAA repeat variation in the GRIK2 gene does not influence age at onset in Huntington's disease. Biochemical and Biophysical Research Communications. 424: 404-8. PMID 22771793 DOI: 10.1016/J.Bbrc.2012.06.120  0.365
2012 Rosas HD, Chen YI, Doros G, Salat DH, Chen NK, Kwong KK, Bush A, Fox J, Hersch SM. Alterations in brain transition metals in Huntington disease: an evolving and intricate story. Archives of Neurology. 69: 887-93. PMID 22393169 DOI: 10.1001/Archneurol.2011.2945  0.325
2012 Lee JM, Gillis T, Mysore JS, Ramos EM, Myers RH, Hayden MR, Morrison PJ, Nance M, Ross CA, Margolis RL, Squitieri F, Griguoli A, Di Donato S, Gomez-Tortosa E, Ayuso C, ... ... Hersch SM, et al. Common SNP-based haplotype analysis of the 4p16.3 Huntington disease gene region. American Journal of Human Genetics. 90: 434-44. PMID 22387017 DOI: 10.1016/J.Ajhg.2012.01.005  0.333
2012 Lee JM, Ramos EM, Lee JH, Gillis T, Mysore JS, Hayden MR, Warby SC, Morrison P, Nance M, Ross CA, Margolis RL, Squitieri F, Orobello S, Di Donato S, Gomez-Tortosa E, ... ... Hersch SM, et al. CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion. Neurology. 78: 690-5. PMID 22323755 DOI: 10.1212/Wnl.0B013E318249F683  0.32
2011 Hu Y, Chopra V, Chopra R, Locascio JJ, Liao Z, Ding H, Zheng B, Matson WR, Ferrante RJ, Rosas HD, Hersch SM, Scherzer CR. Transcriptional modulator H2A histone family, member Y (H2AFY) marks Huntington disease activity in man and mouse. Proceedings of the National Academy of Sciences of the United States of America. 108: 17141-6. PMID 21969577 DOI: 10.1073/Pnas.1104409108  0.372
2011 Maxwell MM, Tomkinson EM, Nobles J, Wizeman JW, Amore AM, Quinti L, Chopra V, Hersch SM, Kazantsev AG. The Sirtuin 2 microtubule deacetylase is an abundant neuronal protein that accumulates in the aging CNS. Human Molecular Genetics. 20: 3986-96. PMID 21791548 DOI: 10.1093/Hmg/Ddr326  0.389
2011 Rosas HD, Reuter M, Doros G, Lee SY, Triggs T, Malarick K, Fischl B, Salat DH, Hersch SM. A tale of two factors: what determines the rate of progression in Huntington's disease? A longitudinal MRI study. Movement Disorders : Official Journal of the Movement Disorder Society. 26: 1691-7. PMID 21611979 DOI: 10.1002/Mds.23762  0.364
2011 Fox JH, Connor T, Stiles M, Kama J, Lu Z, Dorsey K, Lieberman G, Liebermann G, Sapp E, Cherny RA, Banks M, Volitakis I, DiFiglia M, Berezovska O, Bush AI, ... Hersch SM, et al. Cysteine oxidation within N-terminal mutant huntingtin promotes oligomerization and delays clearance of soluble protein. The Journal of Biological Chemistry. 286: 18320-30. PMID 21454633 DOI: 10.1074/Jbc.M110.199448  0.604
2011 Weiss A, Grueninger S, Abramowski D, Giorgio FP, Lopatin MM, Rosas HD, Hersch S, Paganetti P. Microtiter plate quantification of mutant and wild-type huntingtin normalized to cell count. Analytical Biochemistry. 410: 304-6. PMID 21134349 DOI: 10.1016/J.Ab.2010.11.044  0.317
2011 Fox JH, Connor T, Stiles M, Kama J, Lu Z, Dorsey K, Lieberman G, Sapp E, Cherny RA, Banks M, Volitakis I, DiFiglia M, Berezovska O, Bush AI, Hersch SM. Cysteine oxidation within N-terminal mutant huntingtin promotes oligomerization and delays clearance of soluble protein (Journal of Biological Chemistry (2011) 286, (18320-18330)) Journal of Biological Chemistry. 286: 27068. DOI: 10.1074/jbc.A110.199448  0.526
2010 Moscovitch-Lopatin M, Weiss A, Rosas HD, Ritch J, Doros G, Kegel KB, Difiglia M, Kuhn R, Bilbe G, Paganetti P, Hersch S. Optimization of an HTRF Assay for the Detection of Soluble Mutant Huntingtin in Human Buffy Coats: A Potential Biomarker in Blood for Huntington Disease. Plos Currents. 2: RRN1205. PMID 21278900 DOI: 10.1371/Currents.Rrn1205  0.336
2010 Quinti L, Chopra V, Rotili D, Valente S, Amore A, Franci G, Meade S, Valenza M, Altucci L, Maxwell MM, Cattaneo E, Hersch S, Mai A, Kazantsev A. Evaluation of histone deacetylases as drug targets in Huntington's disease models. Study of HDACs in brain tissues from R6/2 and CAG140 knock-in HD mouse models and human patients and in a neuronal HD cell model. Plos Currents. 2. PMID 20877454 DOI: 10.1371/Currents.Rrn1172  0.394
2010 Fox JH, Connor T, Chopra V, Dorsey K, Kama JA, Bleckmann D, Betschart C, Hoyer D, Frentzel S, Difiglia M, Paganetti P, Hersch SM. The mTOR kinase inhibitor Everolimus decreases S6 kinase phosphorylation but fails to reduce mutant huntingtin levels in brain and is not neuroprotective in the R6/2 mouse model of Huntington's disease. Molecular Neurodegeneration. 5: 26. PMID 20569486 DOI: 10.1186/1750-1326-5-26  0.396
2010 Kim J, Amante DJ, Moody JP, Edgerly CK, Bordiuk OL, Smith K, Matson SA, Matson WR, Scherzer CR, Rosas HD, Hersch SM, Ferrante RJ. Reduced creatine kinase as a central and peripheral biomarker in Huntington's disease. Biochimica Et Biophysica Acta. 1802: 673-81. PMID 20460152 DOI: 10.1016/J.Bbadis.2010.05.001  0.416
2010 Ebbel EN, Leymarie N, Schiavo S, Sharma S, Gevorkian S, Hersch S, Matson WR, Costello CE. Identification of phenylbutyrate-generated metabolites in Huntington disease patients using parallel liquid chromatography/electrochemical array/mass spectrometry and off-line tandem mass spectrometry. Analytical Biochemistry. 399: 152-61. PMID 20074541 DOI: 10.1016/J.Ab.2010.01.010  0.314
2010 Rosas HD, Lee SY, Bender AC, Zaleta AK, Vangel M, Yu P, Fischl B, Pappu V, Onorato C, Cha JH, Salat DH, Hersch SM. Altered white matter microstructure in the corpus callosum in Huntington's disease: implications for cortical "disconnection". Neuroimage. 49: 2995-3004. PMID 19850138 DOI: 10.1016/J.Neuroimage.2009.10.015  0.337
2009 Weiss A, Abramowski D, Bibel M, Bodner R, Chopra V, DiFiglia M, Fox J, Kegel K, Klein C, Grueninger S, Hersch S, Housman D, Régulier E, Rosas HD, Stefani M, et al. Single-step detection of mutant huntingtin in animal and human tissues: a bioassay for Huntington's disease. Analytical Biochemistry. 395: 8-15. PMID 19664996 DOI: 10.1016/J.Ab.2009.08.001  0.426
2009 Brocklebank D, Gayán J, Andresen JM, Roberts SA, Young AB, Snodgrass SR, Penney JB, Ramos-Arroyo MA, Cha JJ, Rosas HD, Hersch SM, Feigin A, Cherny SS, Wexler NS, Housman DE, et al. Repeat instability in the 27-39 CAG range of the HD gene in the Venezuelan kindreds: Counseling implications. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics. 150: 425-9. PMID 18712713 DOI: 10.1002/Ajmg.B.30826  0.304
2008 Rosas HD, Salat DH, Lee SY, Zaleta AK, Hevelone N, Hersch SM. Complexity and heterogeneity: what drives the ever-changing brain in Huntington's disease? Annals of the New York Academy of Sciences. 1147: 196-205. PMID 19076442 DOI: 10.1196/Annals.1427.034  0.4
2008 Liu W, Kennington LA, Rosas HD, Hersch S, Cha JH, Zamore PD, Aronin N. Linking SNPs to CAG repeat length in Huntington's disease patients. Nature Methods. 5: 951-3. PMID 18931668 DOI: 10.1038/Nmeth.1261  0.304
2008 Hersch SM, Rosas HD. Neuroprotection for Huntington's disease: ready, set, slow. Neurotherapeutics : the Journal of the American Society For Experimental Neurotherapeutics. 5: 226-36. PMID 18394565 DOI: 10.1016/J.Nurt.2008.01.003  0.38
2008 Rosas HD, Salat DH, Lee SY, Zaleta AK, Pappu V, Fischl B, Greve D, Hevelone N, Hersch SM. Cerebral cortex and the clinical expression of Huntington's disease: complexity and heterogeneity. Brain : a Journal of Neurology. 131: 1057-68. PMID 18337273 DOI: 10.1093/Brain/Awn025  0.362
2007 Stack EC, Dedeoglu A, Smith KM, Cormier K, Kubilus JK, Bogdanov M, Matson WR, Yang L, Jenkins BG, Luthi-Carter R, Kowall NW, Hersch SM, Beal MF, Ferrante RJ. Neuroprotective effects of synaptic modulation in Huntington's disease R6/2 mice. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 27: 12908-15. PMID 18032664 DOI: 10.1523/Jneurosci.4318-07.2007  0.408
2007 Chopra V, Fox JH, Lieberman G, Dorsey K, Matson W, Waldmeier P, Housman DE, Kazantsev A, Young AB, Hersch S. A small-molecule therapeutic lead for Huntington's disease: preclinical pharmacology and efficacy of C2-8 in the R6/2 transgenic mouse. Proceedings of the National Academy of Sciences of the United States of America. 104: 16685-9. PMID 17925440 DOI: 10.1073/Pnas.0707842104  0.643
2007 Sadri-Vakili G, Bouzou B, Benn CL, Kim MO, Chawla P, Overland RP, Glajch KE, Xia E, Qiu Z, Hersch SM, Clark TW, Yohrling GJ, Cha JH. Histones associated with downregulated genes are hypo-acetylated in Huntington's disease models. Human Molecular Genetics. 16: 1293-306. PMID 17409194 DOI: 10.1093/Hmg/Ddm078  0.308
2007 Fox JH, Kama JA, Lieberman G, Chopra R, Dorsey K, Chopra V, Volitakis I, Cherny RA, Bush AI, Hersch S. Mechanisms of copper ion mediated Huntington's disease progression. Plos One. 2: e334. PMID 17396163 DOI: 10.1371/Journal.Pone.0000334  0.615
2007 Kazantsev AG, Hersch SM. Drug targeting of dysregulated transcription in Huntington's disease. Progress in Neurobiology. 83: 249-59. PMID 17379386 DOI: 10.1016/J.Pneurobio.2007.02.005  0.304
2006 Li JL, Hayden MR, Warby SC, Durr A, Morrison PJ, Nance M, Ross CA, Margolis RL, Rosenblatt A, Squitieri F, Frati L, Gómez-Tortosa E, García CA, Suchowersky O, Klimek ML, ... ... Hersch SM, et al. Genome-wide significance for a modifier of age at neurological onset in Huntington's disease at 6q23-24: the HD MAPS study. Bmc Medical Genetics. 7: 71. PMID 16914060 DOI: 10.1186/1471-2350-7-71  0.304
2006 Altmann SM, Muryshev A, Fossale E, Maxwell MM, Norflus FN, Fox J, Hersch SM, Young AB, MacDonald ME, Abagyan R, Kazantsev AG. Discovery of bioactive small-molecule inhibitor of poly adp-ribose polymerase: implications for energy-deficient cells. Chemistry & Biology. 13: 765-70. PMID 16873024 DOI: 10.1016/J.Chembiol.2006.05.012  0.303
2006 Rosas HD, Tuch DS, Hevelone ND, Zaleta AK, Vangel M, Hersch SM, Salat DH. Diffusion tensor imaging in presymptomatic and early Huntington's disease: Selective white matter pathology and its relationship to clinical measures. Movement Disorders : Official Journal of the Movement Disorder Society. 21: 1317-25. PMID 16755582 DOI: 10.1002/Mds.20979  0.34
2006 Qiu Z, Norflus F, Singh B, Swindell MK, Buzescu R, Bejarano M, Chopra R, Zucker B, Benn CL, DiRocco DP, Cha JH, Ferrante RJ, Hersch SM. Sp1 is up-regulated in cellular and transgenic models of Huntington disease, and its reduction is neuroprotective. The Journal of Biological Chemistry. 281: 16672-80. PMID 16595660 DOI: 10.1074/Jbc.M511648200  0.364
2006 Hersch SM, Gevorkian S, Marder K, Moskowitz C, Feigin A, Cox M, Como P, Zimmerman C, Lin M, Zhang L, Ulug AM, Beal MF, Matson W, Bogdanov M, Ebbel E, et al. Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dG. Neurology. 66: 250-2. PMID 16434666 DOI: 10.1212/01.Wnl.0000194318.74946.B6  0.331
2005 Stack EC, Kubilus JK, Smith K, Cormier K, Del Signore SJ, Guelin E, Ryu H, Hersch SM, Ferrante RJ. Chronology of behavioral symptoms and neuropathological sequela in R6/2 Huntington's disease transgenic mice. The Journal of Comparative Neurology. 490: 354-70. PMID 16127709 DOI: 10.1002/Cne.20680  0.386
2005 Ryu H, Rosas HD, Hersch SM, Ferrante RJ. The therapeutic role of creatine in Huntington's disease. Pharmacology & Therapeutics. 108: 193-207. PMID 16055197 DOI: 10.1016/J.Pharmthera.2005.04.008  0.402
2005 Puri BK, Leavitt BR, Hayden MR, Ross CA, Rosenblatt A, Greenamyre JT, Hersch S, Vaddadi KS, Sword A, Horrobin DF, Manku M, Murck H. Ethyl-EPA in Huntington disease: a double-blind, randomized, placebo-controlled trial. Neurology. 65: 286-92. PMID 16043801 DOI: 10.1212/01.Wnl.0000169025.09670.6D  0.328
2005 Borovecki F, Lovrecic L, Zhou J, Jeong H, Then F, Rosas HD, Hersch SM, Hogarth P, Bouzou B, Jensen RV, Krainc D. Genome-wide expression profiling of human blood reveals biomarkers for Huntington's disease Proceedings of the National Academy of Sciences of the United States of America. 102: 11023-11028. PMID 16043692 DOI: 10.1073/Pnas.0504921102  0.356
2004 Hersch SM, Ferrante RJ. Translating therapies for Huntington's disease from genetic animal models to clinical trials. Neurorx : the Journal of the American Society For Experimental Neurotherapeutics. 1: 298-306. PMID 15717031 DOI: 10.1602/Neurorx.1.3.298  0.357
2004 Rosas HD, Feigin AS, Hersch SM. Using advances in neuroimaging to detect, understand, and monitor disease progression in Huntington's disease. Neurorx : the Journal of the American Society For Experimental Neurotherapeutics. 1: 263-72. PMID 15717027 DOI: 10.1602/Neurorx.1.2.263  0.362
2004 Norflus F, Nanje A, Gutekunst CA, Shi G, Cohen J, Bejarano M, Fox J, Ferrante RJ, Hersch SM. Anti-inflammatory treatment with acetylsalicylate or rofecoxib is not neuroprotective in Huntington's disease transgenic mice. Neurobiology of Disease. 17: 319-25. PMID 15474369 DOI: 10.1016/J.Nbd.2004.07.011  0.35
2004 Fox JH, Barber DS, Singh B, Zucker B, Swindell MK, Norflus F, Buzescu R, Chopra R, Ferrante RJ, Kazantsev A, Hersch SM. Cystamine increases L-cysteine levels in Huntington's disease transgenic mouse brain and in a PC12 model of polyglutamine aggregation. Journal of Neurochemistry. 91: 413-22. PMID 15447674 DOI: 10.1111/J.1471-4159.2004.02726.X  0.404
2004 Wexler NS, Lorimer J, Porter J, Gomez F, Moskowitz C, Shackell E, Marder K, Penchaszadeh G, Roberts SA, Gayán J, Brocklebank D, Cherny SS, Cardon LR, Gray J, Dlouhy SR, ... ... Hersch S, et al. Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington's disease age of onset. Proceedings of the National Academy of Sciences of the United States of America. 101: 3498-503. PMID 14993615 DOI: 10.1073/Pnas.0308679101  0.313
2003 Hersch S, Fink K, Vonsattel JP, Friedlander RM. Minocycline is protective in a mouse model of Huntington's disease. Annals of Neurology. 54: 841; author reply 84. PMID 14681897 DOI: 10.1002/Ana.21891  0.351
2003 Ferrante RJ, Kubilus JK, Lee J, Ryu H, Beesen A, Zucker B, Smith K, Kowall NW, Ratan RR, Luthi-Carter R, Hersch SM. Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 23: 9418-27. PMID 14561870 DOI: 10.1523/Jneurosci.23-28-09418.2003  0.404
2003 Li JL, Hayden MR, Almqvist EW, Brinkman RR, Durr A, Dodé C, Morrison PJ, Suchowersky O, Ross CA, Margolis RL, Rosenblatt A, Gómez-Tortosa E, Cabrero DM, Novelletto A, Frontali M, ... ... Hersch SM, et al. A genome scan for modifiers of age at onset in Huntington disease: The HD MAPS study. American Journal of Human Genetics. 73: 682-7. PMID 12900792 DOI: 10.1086/378133  0.323
2003 Dedeoglu A, Kubilus JK, Yang L, Ferrante KL, Hersch SM, Beal MF, Ferrante RJ. Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice. Journal of Neurochemistry. 85: 1359-67. PMID 12787055 DOI: 10.1046/J.1471-4159.2003.01706.X  0.399
2003 Apostol BL, Kazantsev A, Raffioni S, Illes K, Pallos J, Bodai L, Slepko N, Bear JE, Gertler FB, Hersch S, Housman DE, Marsh JL, Thompson LM. A cell-based assay for aggregation inhibitors as therapeutics of polyglutamine-repeat disease and validation in Drosophila. Proceedings of the National Academy of Sciences of the United States of America. 100: 5950-5. PMID 12730384 DOI: 10.1073/Pnas.2628045100  0.329
2002 Singaraja RR, Hadano S, Metzler M, Givan S, Wellington CL, Warby S, Yanai A, Gutekunst CA, Leavitt BR, Yi H, Fichter K, Gan L, McCutcheon K, Chopra V, Michel J, ... Hersch SM, et al. HIP14, a novel ankyrin domain-containing protein, links huntingtin to intracellular trafficking and endocytosis. Human Molecular Genetics. 11: 2815-28. PMID 12393793 DOI: 10.1093/Hmg/11.23.2815  0.39
2002 Dedeoglu A, Kubilus JK, Jeitner TM, Matson SA, Bogdanov M, Kowall NW, Matson WR, Cooper AJ, Ratan RR, Beal MF, Hersch SM, Ferrante RJ. Therapeutic effects of cystamine in a murine model of Huntington's disease. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 22: 8942-50. PMID 12388601 DOI: 10.1523/Jneurosci.22-20-08942.2002  0.429
2002 Wellington CL, Ellerby LM, Gutekunst CA, Rogers D, Warby S, Graham RK, Loubser O, van Raamsdonk J, Singaraja R, Yang YZ, Gafni J, Bredesen D, Hersch SM, Leavitt BR, Roy S, et al. Caspase cleavage of mutant huntingtin precedes neurodegeneration in Huntington's disease. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 22: 7862-72. PMID 12223539 DOI: 10.1523/Jneurosci.22-18-07862.2002  0.409
2002 Meade CA, Deng YP, Fusco FR, Del Mar N, Hersch S, Goldowitz D, Reiner A. Cellular localization and development of neuronal intranuclear inclusions in striatal and cortical neurons in R6/2 transgenic mice. The Journal of Comparative Neurology. 449: 241-69. PMID 12115678 DOI: 10.1002/Cne.10295  0.363
2002 Kiechle T, Dedeoglu A, Kubilus J, Kowall NW, Beal MF, Friedlander RM, Hersch SM, Ferrante RJ. Cytochrome C and caspase-9 expression in Huntington's disease. Neuromolecular Medicine. 1: 183-95. PMID 12095160 DOI: 10.1385/Nmm:1:3:183  0.357
2002 Dunah AW, Jeong H, Griffin A, Kim YM, Standaert DG, Hersch SM, Mouradian MM, Young AB, Tanese N, Krainc D. Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease. Science (New York, N.Y.). 296: 2238-43. PMID 11988536 DOI: 10.1126/Science.1072613  0.418
2002 Wheeler VC, Gutekunst CA, Vrbanac V, Lebel LA, Schilling G, Hersch S, Friedlander RM, Gusella JF, Vonsattel JP, Borchelt DR, MacDonald ME. Early phenotypes that presage late-onset neurodegenerative disease allow testing of modifiers in Hdh CAG knock-in mice. Human Molecular Genetics. 11: 633-40. PMID 11912178 DOI: 10.1093/Hmg/11.6.633  0.443
2002 Rosas HD, Liu AK, Hersch S, Glessner M, Ferrante RJ, Salat DH, van der Kouwe A, Jenkins BG, Dale AM, Fischl B. Regional and progressive thinning of the cortical ribbon in Huntington's disease. Neurology. 58: 695-701. PMID 11889230 DOI: 10.1212/Wnl.58.5.695  0.381
2002 Ferrante RJ, Andreassen OA, Dedeoglu A, Ferrante KL, Jenkins BG, Hersch SM, Beal MF. Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's disease. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 22: 1592-9. PMID 11880489 DOI: 10.1523/Jneurosci.22-05-01592.2002  0.355
2001 Andreassen OA, Dedeoglu A, Ferrante RJ, Jenkins BG, Ferrante KL, Thomas M, Friedlich A, Browne SE, Schilling G, Borchelt DR, Hersch SM, Ross CA, Beal MF. Creatine increase survival and delays motor symptoms in a transgenic animal model of Huntington's disease. Neurobiology of Disease. 8: 479-91. PMID 11447996 DOI: 10.1006/Nbdi.2001.0406  0.394
2001 Hersch SM, Rosas HD. Neuroprotective therapy for Huntington's disease: New prospects and challenges Expert Review of Neurotherapeutics. 1: 111-118. DOI: 10.1586/14737175.1.1.111  0.389
2000 Freeman TB, Cicchetti F, Hauser RA, Deacon TW, Li XJ, Hersch SM, Nauert GM, Sanberg PR, Kordower JH, Saporta S, Isacson O. Transplanted fetal striatum in Huntington's disease: phenotypic development and lack of pathology. Proceedings of the National Academy of Sciences of the United States of America. 97: 13877-82. PMID 11106399 DOI: 10.1073/Pnas.97.25.13877  0.355
2000 Gutekunst CA, Norflus F, Hersch SM. Recent advances in Huntington's disease. Current Opinion in Neurology. 13: 445-50. PMID 10970063 DOI: 10.1097/00019052-200008000-00013  0.4
2000 Ferrante RJ, Andreassen OA, Jenkins BG, Dedeoglu A, Kuemmerle S, Kubilus JK, Kaddurah-Daouk R, Hersch SM, Beal MF. Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 20: 4389-97. PMID 10844007 DOI: 10.1523/Jneurosci.20-12-04389.2000  0.404
2000 Wheeler VC, White JK, Gutekunst CA, Vrbanac V, Weaver M, Li XJ, Li SH, Yi H, Vonsattel JP, Gusella JF, Hersch S, Auerbach W, Joyner AL, MacDonald ME. Long glutamine tracts cause nuclear localization of a novel form of huntingtin in medium spiny striatal neurons in HdhQ92 and HdhQ111 knock-in mice. Human Molecular Genetics. 9: 503-13. PMID 10699173 DOI: 10.1093/Hmg/9.4.503  0.421
1999 Kuemmerle S, Gutekunst CA, Klein AM, Li XJ, Li SH, Beal MF, Hersch SM, Ferrante RJ. Huntington aggregates may not predict neuronal death in Huntington's disease. Annals of Neurology. 46: 842-9. PMID 10589536 DOI: 10.1002/1531-8249(199912)46:6<842::Aid-Ana6>3.0.Co;2-O  0.364
1999 Hackam AS, Hodgson JG, Singaraja R, Zhang T, Gan L, Gutekunst CA, Hersch SM, Hayden MR. Evidence for both the nucleus and cytoplasm as subcellular sites of pathogenesis in Huntington's disease in cell culture and in transgenic mice expressing mutant huntingtin. Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences. 354: 1047-55. PMID 10434304 DOI: 10.1098/Rstb.1999.0457  0.397
1999 Hodgson JG, Agopyan N, Gutekunst CA, Leavitt BR, LePiane F, Singaraja R, Smith DJ, Bissada N, McCutcheon K, Nasir J, Jamot L, Li XJ, Stevens ME, Rosemond E, Roder JC, ... ... Hersch SM, et al. A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration. Neuron. 23: 181-92. PMID 10402204 DOI: 10.1016/S0896-6273(00)80764-3  0.415
1999 Gutekunst CA, Li SH, Yi H, Mulroy JS, Kuemmerle S, Jones R, Rye D, Ferrante RJ, Hersch SM, Li XJ. Nuclear and neuropil aggregates in Huntington's disease: relationship to neuropathology. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 19: 2522-34. PMID 10087066 DOI: 10.1523/Jneurosci.19-07-02522.1999  0.394
1998 Li SH, Gutekunst CA, Hersch SM, Li XJ. Association of HAP1 isoforms with a unique cytoplasmic structure. Journal of Neurochemistry. 71: 2178-85. PMID 9798945 DOI: 10.1046/J.1471-4159.1998.71052178.X  0.31
1998 Klement IA, Skinner PJ, Kaytor MD, Yi H, Hersch SM, Clark HB, Zoghbi HY, Orr HT. Ataxin-1 nuclear localization and aggregation: role in polyglutamine-induced disease in SCA1 transgenic mice. Cell. 95: 41-53. PMID 9778246 DOI: 10.1016/S0092-8674(00)81781-X  0.333
1998 Gutekunst CA, Li SH, Yi H, Ferrante RJ, Li XJ, Hersch SM. The cellular and subcellular localization of huntingtin-associated protein 1 (HAP1): comparison with huntingtin in rat and human. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 18: 7674-86. PMID 9742138 DOI: 10.1523/Jneurosci.18-19-07674.1998  0.367
1998 Li SH, Hosseini SH, Gutekunst CA, Hersch SM, Ferrante RJ, Li XJ. A human HAP1 homologue. Cloning, expression, and interaction with huntingtin. The Journal of Biological Chemistry. 273: 19220-7. PMID 9668110 DOI: 10.1074/Jbc.273.30.19220  0.349
1998 Li SH, Gutekunst CA, Hersch SM, Li XJ. Interaction of huntingtin-associated protein with dynactin P150Glued. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 18: 1261-9. PMID 9454836 DOI: 10.1523/Jneurosci.18-04-01261.1998  0.326
1997 Ordway JM, Tallaksen-Greene S, Gutekunst CA, Bernstein EM, Cearley JA, Wiener HW, Dure LS, Lindsey R, Hersch SM, Jope RS, Albin RL, Detloff PJ. Ectopically expressed CAG repeats cause intranuclear inclusions and a progressive late onset neurological phenotype in the mouse. Cell. 91: 753-63. PMID 9413985 DOI: 10.1016/S0092-8674(00)80464-X  0.354
1997 Feng Y, Gutekunst CA, Eberhart DE, Yi H, Warren ST, Hersch SM. Fragile X mental retardation protein: nucleocytoplasmic shuttling and association with somatodendritic ribosomes. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 17: 1539-47. PMID 9030614 DOI: 10.1523/Jneurosci.17-05-01539.1997  0.334
1997 Hersch SM, Gutekunst C, Ferrante RJ. NEOSTRIATAL HUNTINGTIN IMMUNOREACTIVITY CORRELATES WITH VULNERABILITY TO NEURODEGENERATION IN HUNTINGTONʼS DISEASE Journal of Neuropathology and Experimental Neurology. 56: 588. DOI: 10.1097/00005072-199705000-00081  0.344
1996 Gilmor ML, Nash NR, Roghani A, Edwards RH, Yi H, Hersch SM, Levey AI. Expression of the putative vesicular acetylcholine transporter in rat brain and localization in cholinergic synaptic vesicles. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 16: 2179-90. PMID 8601799 DOI: 10.1523/Jneurosci.16-07-02179.1996  0.337
1995 Gutekunst CA, Levey AI, Heilman CJ, Whaley WL, Yi H, Nash NR, Rees HD, Madden JJ, Hersch SM. Identification and localization of huntingtin in brain and human lymphoblastoid cell lines with anti-fusion protein antibodies. Proceedings of the National Academy of Sciences of the United States of America. 92: 8710-4. PMID 7568002 DOI: 10.1073/Pnas.92.19.8710  0.394
1995 Ciliax BJ, Heilman C, Demchyshyn LL, Pristupa ZB, Ince E, Hersch SM, Niznik HB, Levey AI. The dopamine transporter: immunochemical characterization and localization in brain. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 15: 1714-23. PMID 7534339 DOI: 10.1523/Jneurosci.15-03-01714.1995  0.307
1994 Hersch SM, Jones R, Koroshetz W, Quaid K. The neurogenetics genie: Testing for the huntington's disease mutation Neurology. 44: 1369-1373. PMID 7914682 DOI: 10.1212/Wnl.44.8.1369  0.304
1992 Green RC, Goldstein FC, Auchus AP, Presley R, Clark WS, Van Tuyl L, Green J, Hersch SM, Karp HR. Treatment trial of oxiracetam in Alzheimer's disease. Archives of Neurology. 49: 1135-6. PMID 1444879 DOI: 10.1001/Archneur.1992.00530350049018  0.313
Show low-probability matches.